Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFXIII (catridecacog) in mild to moderate active ulcerative colitis
2011-001568-22Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing catridecacog with placebo (2 arms). Primary endpoint: Endoscopic remission (primary). Started Jul 2012; status: terminated.
02
Drugs
catridecacog
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-001568-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001568-22.